Remove Clinical Trials Remove Development Remove Life Science
article thumbnail

Tiziana Life Sciences plans to assess intranasal foralumab for long Covid

Pharmaceutical Technology

Biotechnology company Tiziana Life Sciences has revealed plans to assess intranasal foralumab as a potential treatment for long Covid. Long Covid is a health condition characterised by the continuation or development of new symptoms three months after an initial SARS-CoV-2 infection.

article thumbnail

GSK and Wave Life Sciences partner to develop oligonucleotide therapeutics

Pharmaceutical Technology

GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The discovery alliance, with a preliminary research period of four years, will aid GSK in progressing up to eight programmes and Wave to develop up to three programmes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

TORL BioTherapeutics raises funds to develop new oncology therapies

Pharmaceutical Technology

Clinical-stage biopharmaceutical company TORL BioTherapeutics has raised $158m in a Series B financing round for advancing the development of new biologics for cancer treatment. TORL BioTherapeutics is a newly formed, US-based company focused on the development of novel antibody-based therapeutics for cancer patients.

article thumbnail

Indian life sciences sector integrating technologies in R&D efforts

AuroBlog - Aurous Healthcare Clinical Trials blog

The Indian life sciences sector is making strides by integrating quantum computing, artificial intelligence (AI), machine learning (ML), advanced analytics, big data, internet of things (IoT) and blockchain into their research and development efforts.

article thumbnail

How the New EU AI Act Will Impact Clinical Trials in the Life Sciences?

Cloudbyz

This Act is poised to significantly change the clinical trials landscape within the life sciences sector. As AI increasingly becomes a cornerstone in clinical research and drug development, it is crucial for industry stakeholders to grasp the extensive implications of this regulation.

article thumbnail

Aviceda, QUB to develop next-generation glyco-immune therapeutics

Pharmaceutical Technology

Aviceda Therapeutics (Aviceda) has entered into a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (QUB) for the development of next-generation glyco-immune therapeutics. Aviceda Glycotech has been created as an oncology-focused spin-off company from Aviceda Therapeutics and Queen’s.

article thumbnail

Industry calls for boosting innovation and investment in NCEs and NBEs to propel life sciences growth

AuroBlog - Aurous Healthcare Clinical Trials blog

As the Union Budget approaches, the life sciences sector anticipates substantial support to enhance innovation and investment in the development of new chemical entities (NCEs) and new biological entities (NBEs). The life sciences sector in India has shown remarkable resilience […]